GSBR-1290
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| DrugBank | |
GSBR-1290 is a small-molecule GLP-1 agonist developed by Structure Therapeutics.[1] It is delivered orally and is in a Phase II trial as of 2023.[2][3][4] On 18 December 2023 trial results failed to meet exceptions and Structure Therapeutics share price lost half its value.[5]
References[edit]
- ^ Mao, Ting; Meng, Qinghua; Zhang, Haizhen; Zhang, Jinqiang J.; Shi, Songting; Guan, Zhibo; Jiang, Xinglong; Zhang, Fang; Lei, Hui; Lin, Xichen (20 June 2023). "760-P: Discovery of GSBR-1290, a Highly Potent, Orally Available, Novel Small Molecule GLP-1 Receptor Agonist". Diabetes. 72 (Supplement_1). doi:10.2337/db23-760-P. S2CID 259430363.
- ^ "Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity". BioSpace. Retrieved 4 November 2023.
- ^ "Structure announces positive results from oral GLP-1 receptor agonist gsbr-1290". Bariatric News. 2 October 2023. Retrieved 4 November 2023.
- ^ Satija, Bhanvi (29 September 2023). "Structure Therapeutics surges as early data from obesity pill tops expectations". Reuters. Retrieved 4 November 2023.
- ^ Iskowitz, Marc (19 December 2023). "Structure's GLP-1 pill is safe, but diabetes efficacy lags Lilly's asset". MM+M - Medical Marketing and Media. Retrieved 1 January 2024.